The prognosis is best when identified early and treated aggressively. In these cases<unk>  is not usually fatal. In earlier studies the mortality rates from<unk>  ranged from 20%–38%, but by 2009 mortality rates were reported to have fallen below 10% over the previous two decades due to early recognition and improved management. Re-introduction to the drug that originally caused<unk>  to develop may also trigger a recurrence, although in most cases it does not. Memory impairment is a consistent feature of recovery from<unk> , and is usually temporary though in some cases may become persistent.
Neuroleptic malignant syndrome
Malignant hyperthermia
Limbic encephalitis
Catatonia
Viral encephalitis
Serotonin syndrome
Oculogyric crisis
Heat stroke